IBI has inaugurated a collaboration for an innovative and integrated cell line by the use of kits CHOvolutionTM. This partnership will strengthen the biotech department capacity in the preliminary stages of the production process and will allow us to offer a complete service to our business partners who want to quickly enter clinical trials.
IBI and Celonic together provide a secure and tested development platform to customers around the world.
IBI faces the new therapy challenges of the pharmaceutical market by offering the development and cGMP production of recombinant proteins and mAbs from mammalian cells (CHO) for IMP.
For full information visit www.ibi-lorenzini.com